Genmab enters agreement on cancer biomarker
A supply agreement will give the Danish firm access to US-based biotech company Imaginab’s oncology imaging technology in future clinical trials.
by christian bundgaard, translated by daniel pedersen
Danish biotech firm Genmab has struck a supply deal with Imaginab, a US-based biotech firm that is developing imaging technology for cancer treatments, the latter firm has announced in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Cancer drug hope raises Genmab's spirits after legal defeat
For subscribers
.jpg&w=384&q=75)
